Search
SOLACI Congress
Day 2

IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock.

solaci
solaci
286
0

 IABP-SHOCK II: Intra-aortic balloon use impact on 30-day mortality in patients with cardiogenic shock. 

IABP-shock-artigo
Holger Thiele
2012-08-26

Original title: IABP-SHOCK II: Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock

Previous article
PROTECT: A comparison of thrombosis incidence between the drug-eluting stents sirolimus and zotarolimus.
Next article
FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.
solaci
solaci

More articles by this author

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

solaci - 0
Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers. Procedural success was high,...

GRACE: Use of insulin glargine and fatty acids to reduce atherosclerosis progression.

solaci - 0
Presentation Summary: There is a clear association between hyperglycemia and the development of atherosclerosis. The GRACE sub trial, (from ORIGIN study), evaluated the administration...

GARY: German Aortic Valve Registry.

solaci - 0
Presentation Summary: The German Aortic Stenosis Registry collected data from German centers. 13,860 patients who were undergoing valve replacement surgery or percutaneous valve implant...

FAST MI: AMI improved the survival associated with the clinical characteristics changes of patients in the French National Registry.

solaci - 0
Presentation Summary: The French National Registry included patients admitted with acute myocardial infarction between 1995 and 2010 (n = 6707). Over time, authors noted...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Day 2

ACCESS-EUROPE: 12 months results in percutaneous treatment of mitral insufficiency .

Presentation Summary: ACCESS-EUROPE multicenter registry included 567 patients with severe mitral regurgitation treated with Mitral Clip in 14 European centers....
solaci -
SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy